Robert Driscoll Analyst PerformanceSenior Vice President, Equity Research at WedbushRobert Driscoll is a stock analyst at Wedbush in the healthcare sector, covering 34 publicly traded companies. Over the past year, Robert Driscoll has issued 83 stock ratings, including buy, hold, and sell recommendations. While full access to Robert Driscoll's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Driscoll's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings184 Last 9 YearsBuy Recommendations79.78% 146 Buy RatingsCompanies Covered34 Unique Companies Ratings Distribution183RatingsDistribution of strong buy, buy, hold, and sell ratings by Robert Driscoll.RatingPercentageCount Strong Buy0.5%1 ratings Buy79.2%145 ratings Hold16.9%31 ratings Sell3.3%6 ratingsOut of 183 total stock ratings issued by Robert Driscoll at Wedbush, the majority (79.2%) have been Buy recommendations, followed by 16.9% Hold, 3.3% Sell, and 0.5% Strong Buy.Best & Worst CallsBest Call0000.0%ALPNMar 2023Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BDTXJan 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ94.1% of companies on NASDAQ32 companiesNYSE2.9% of companies on NYSE1 companyOTCMKTS2.9% of companies on OTCMKTS1 companyRobert Driscoll, an analyst at Wedbush, currently covers 34 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare34 companies100.0%Robert Driscoll of Wedbush specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY30 companies88.2%PHARMACEUTICALS4 companies11.8% About Robert DriscollRobert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Arvinas (ARVN), Kura Oncology (KURA), Arcus Biosciences (RCUS), and IGM Biosciences (IGMS). Robert received his Bachelor’s degree in Biochemistry from the University of Leeds, and his Ph.D. in Cellular and Molecular Biology from the University of Cambridge. He also completed a postdoctoral fellowship at Stanford University.Follow on LinkedIn Robert Driscoll's Ratings History at Wedbush Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCGONCG Oncology11/17/2026Boost Price Target$84.78$91.00Outperform$0.0000.00% ROITYRATyra Biosciences11/11/2026Boost Price Target$21.00$57.00Outperform$0.0000.00% ROICGEMCullinan Therapeutics11/11/2026Boost Price Target$11.23$44.00Outperform$0.0000.00% ROIZNTLZentalis Pharmaceuticals11/10/2026Upgrade$1.74$6.00Outperform$0.0000.00% ROITNGXTango Therapeutics11/10/2026Lower Price Target$23.66$40.00Outperform$0.0000.00% ROICMPXCompass Therapeutics11/10/2026Lower Price Target$0.87$0.90Neutral$0.0000.00% ROICTMXCytomX Therapeutics11/6/2026Boost Price Target$2.19$12.00Outperform$0.0000.00% ROIJANXJanux Therapeutics11/6/2026Boost Price Target$16.83$40.00Outperform$0.0000.00% ROIPYXSPyxis Oncology11/6/2026Lower Price Target$1.67$7.00Outperform$0.0000.00% ROIAVTXAvalo Therapeutics11/6/2026Lower Price Target$6.75$20.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CGONCG Oncology11/6/2026Boost Price Target$74.68$84.00Outperform$0.0000.00% ROIRCUSArcus Biosciences11/5/2026Lower Price Target$19.32$45.00Outperform$0.0000.00% ROIIDYAIDEAYA Biosciences11/4/2026Boost Price Target$31.72$63.00Outperform$0.0000.00% ROIGERNGeron10/28/2026Lower Price Target$0.90$5.00Outperform$0.0000.00% ROIAVTXAvalo Therapeutics10/23/2026Lower Price Target$7.45$22.00Outperform$0.0000.00% ROIRCUSArcus Biosciences10/21/2026Boost Price Target$23.69$49.00Outperform$0.0000.00% ROIFHTXFoghorn Therapeutics10/2/2026Downgrade$2.92$2.00Neutral$0.0000.00% ROIRCUSArcus Biosciences9/30/2026Reiterated Rating$25.67$43.00Outperform$0.0000.00% ROIACETAdicet Bio9/28/2026Reiterated Rating$6.52$28.00Outperform$0.0000.00% ROICMPXCompass Therapeutics9/23/2026Set Price Target$1.24$4.00$0.0000.00% ROICMPXCompass Therapeutics9/22/2026Downgrade$1.24$1.00Neutral$0.0000.00% ROICBIOCrescent Biopharma9/14/2026Reiterated Rating$19.41$27.00Outperform$0.0000.00% ROIPYXSPyxis Oncology9/10/2026Boost Price Target$3.38$8.00Outperform$0.0000.00% ROITYRATyra Biosciences9/10/2026Reiterated Rating$22.01$53.00Outperform$0.0000.00% ROIGLUEMonte Rosa Therapeutics9/9/2026Reiterated Rating$14.27$27.00Outperform$0.0000.00% ROIRVMDRevolution Medicines8/27/2026Boost Price Target$219.02$225.00Outperform$0.0000.00% ROICBIOCrescent Biopharma8/27/2026Reiterated Rating$17.80$27.00Outperform$0.0000.00% ROIEIKNEikon Therapeutics8/14/2026Lower Price Target$9.86$4.00Underperform$0.0000.00% ROICGEMCullinan Therapeutics8/13/2026Boost Price Target$19.60$42.00Outperform$0.0000.00% ROIKURAKura Oncology8/13/2026Boost Price Target$9.94$38.00Outperform$0.0000.00% ROIAPREAprea Therapeutics8/13/2026Lower Price Target$0.68$3.00Outperform$0.0000.00% ROIREPLReplimune Group8/7/2026Upgrade$12.86$12.00Outperform$0.0000.00% ROIRVMDRevolution Medicines8/6/2026Boost Price Target$198.97$201.00Outperform$0.0000.00% ROIRCUSArcus Biosciences8/6/2026Boost Price Target$27.92$43.00Outperform$0.0000.00% ROIIDYAIDEAYA Biosciences8/5/2026Boost Price Target$36.11$60.00Outperform$0.0000.00% ROIARVNArvinas8/5/2026Boost Price Target$9.00$12.00Neutral$0.0000.00% ROIGLUEMonte Rosa Therapeutics8/3/2026Lower Price Target$16.57$27.00Outperform$0.0000.00% ROIREPLReplimune Group7/31/2026Upgrade$5.50$12.00Outperform$0.0000.00% ROIKURAKura Oncology7/28/2026Reiterated Rating$10.15$36.00Outperform$0.0000.00% ROIRVMDRevolution Medicines7/23/2026Boost Price Target$190.09$192.10Outperform$0.0000.00% ROIWhy I'm selling my Snapback Indicator for just $7 (Ad)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.Get lifetime access to the Snapback Indicator for a one-time $7 payment today.RVMDRevolution Medicines7/2/2026Boost Price Target$185.36$181.00Outperform$0.0000.00% ROIREPLReplimune Group6/30/2026Boost Price Target$11.20$9.00Neutral$0.0000.00% ROIIDYAIDEAYA Biosciences6/12/2026Reiterated Rating$29.45$58.00Outperform$0.0000.00% ROICGEMCullinan Therapeutics6/11/2026Reiterated Rating$12.11$37.00Outperform$0.0000.00% ROIIDYAIDEAYA Biosciences6/2/2026Reiterated Rating$28.94$58.00Outperform$0.0000.00% ROIRVMDRevolution Medicines6/1/2026Reiterated Rating$163.40Outperform$0.0000.00% ROIREPLReplimune Group6/1/2026Boost Price Target$9.19$6.00Neutral$0.0000.00% ROICRBPCorbus Pharmaceuticals5/27/2026Lower Price Target$7.91$30.00Outperform$0.0000.00% ROIAVTXAvalo Therapeutics5/14/2026Lower Price Target$19.85$34.00Outperform$0.0000.00% ROITNGXTango Therapeutics5/14/2026Boost Price Target$23.72$33.00Outperform$0.0000.00% ROIAPREAprea Therapeutics5/14/2026Lower Price Target$0.90$6.00Outperform$0.0000.00% ROIEIKNEikon Therapeutics5/12/2026Lower Price Target$9.95$5.00Underperform$0.0000.00% ROICGEMCullinan Therapeutics5/8/2026Boost Price Target$14.96$37.00Outperform$0.0000.00% ROIJANXJanux Therapeutics5/8/2026Lower Price Target$14.30$36.00Outperform$0.0000.00% ROIRVMDRevolution Medicines5/7/2026Boost Price Target$144.46$165.00Outperform$0.0000.00% ROIAVTXAvalo Therapeutics5/6/2026Boost Price Target$16.26$40.00Outperform$0.0000.00% ROIPYXSPyxis Oncology5/5/2026Initiated Coverage$1.76$6.00Outperform$0.0000.00% ROIIDYAIDEAYA Biosciences4/14/2026Boost Price Target$30.82$58.00Outperform$0.0000.00% ROIRVMDRevolution Medicines4/14/2026Reiterated Rating$138.88Outperform$0.0000.00% ROIREPLReplimune Group4/13/2026Downgrade$4.77$2.00Neutral$0.0000.00% ROIRCUSArcus Biosciences4/2/2026Boost Price Target$21.89$41.00Outperform$0.0000.00% ROIEIKNEikon Therapeutics3/31/2026Reiterated Rating$10.03$7.00Underperform$0.0000.00% ROIIDYAIDEAYA Biosciences3/31/2026Reiterated Rating$33.36$52.00Outperform$0.0000.00% ROIAPREAprea Therapeutics3/31/2026Reiterated Rating$0.74$7.00Outperform$0.0000.00% ROIBDTXBlack Diamond Therapeutics3/17/2026Boost Price Target$2.19$14.00Outperform$0.0000.00% ROICTMXCytomX Therapeutics3/17/2026Boost Price Target$6.75$11.00Outperform$0.0000.00% ROIFHTXFoghorn Therapeutics3/12/2026Reiterated Rating$4.87$10.00Outperform$0.0000.00% ROICGEMCullinan Therapeutics3/11/2026Boost Price Target$14.91$36.00Outperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals3/9/2026Downgrade$21.20$21.50Neutral$0.0000.00% ROIKURAKura Oncology3/6/2026Lower Price Target$8.51$36.00Outperform$0.0000.00% ROITNGXTango Therapeutics3/6/2026Boost Price Target$16.80$19.00Outperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals3/6/2026Downgrade$21.20Hold$0.0000.00% ROIEIKNEikon Therapeutics2/26/2026Initiated Coverage$14.89$7.00Underperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals2/25/2026Boost Price Target$12.02$30.00Outperform$0.0000.00% ROIARVNArvinas2/24/2026Boost Price Target$11.99$11.00Neutral$0.0000.00% ROIIDYAIDEAYA Biosciences2/18/2026Boost Price Target$30.76$52.00Outperform$0.0000.00% ROITYRATyra Biosciences2/13/2026Boost Price Target$29.60$53.00Outperform$0.0000.00% ROIAPREAprea Therapeutics2/10/2026Lower Price Target$0.64$7.00Outperform$0.0000.00% ROIREPLReplimune Group2/4/2026Boost Price Target$7.35$19.00Outperform$0.0000.00% ROIRVMDRevolution Medicines1/9/2026Reiterated Rating$107.39$147.00Outperform$0.0000.00% ROITYRATyra Biosciences12/16/2025Boost Price Target$22.12$37.00Outperform$0.0000.00% ROICGONCG Oncology12/11/2025Initiated Coverage$41.74$70.00Outperform$0.0000.00% ROICGEMCullinan Therapeutics12/9/2025Boost Price Target$12.44$34.00Outperform$0.0000.00% ROIKURAKura Oncology11/14/2025Reiterated Rating$10.68$38.00Outperform$0.0000.00% ROIRVMDRevolution Medicines11/6/2025Boost Price Target$59.34$80.00Outperform$000.0000.00% ROIREPLReplimune Group10/20/2025Upgrade$4.50$18.00Outperform$00.0000.00% ROICRBPCorbus Pharmaceuticals10/20/2025Boost Price Target$19.32$38.00Outperform$0.0000.00% ROIRVMDRevolution Medicines10/17/2025Reiterated Rating$49.68$77.00Outperform$000.0000.00% ROIRVMDRevolution Medicines9/11/2025Boost Price Target$40.45$77.00Outperform$000.0000.00% ROIREPLReplimune Group7/22/2025Reiterated Rating$3.14$4.00Neutral$00.0000.00% ROIWhat the hell is going on? (Ad)Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.Watch Porter Stansberry's full broadcast on the coming dollar reset nowCBIOCrescent Biopharma7/14/2025Initiated Coverage$12.96$27.00Outperform$00.0000.00% ROIKURAKura Oncology6/20/2025Reiterated Rating$6.06$36.00Outperform$00.0000.00% ROIZNTLZentalis Pharmaceuticals5/15/2025Reiterated Rating$1.18$4.00Neutral$0.0000.00% ROIHOWLWerewolf Therapeutics5/9/2025Lower Price Target$0.82$6.00Outperform$0.0000.00% ROIRVMDRevolution Medicines4/28/2025Reiterated Rating$41.02$67.00Outperform$000.0000.00% ROIZNTLZentalis Pharmaceuticals3/28/2025Reiterated Rating$1.70$4.00Neutral$0.0000.00% ROIAVTXAvalo Therapeutics3/20/2025Reiterated Rating$8.04$18.00Outperform$00.0000.00% ROIGLUEMonte Rosa Therapeutics3/20/2025Reiterated Rating$7.06$17.00Outperform$00.0000.00% ROIARVNArvinas3/12/2025Downgrade$8.30$12.00Neutral$00.0000.00% ROIHOWLWerewolf Therapeutics3/12/2025Reiterated Rating$1.30$8.00Outperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals2/26/2025Reiterated Rating$10.25$32.00Outperform$00.0000.00% ROIAVTXAvalo Therapeutics2/20/2025Upgrade$8.44Strong-Buy$00.0000.00% ROIKURAKura Oncology2/6/2025Boost Price Target$8.13$36.00Outperform$0.0000.00% ROIZNTLZentalis Pharmaceuticals1/24/2025Reiterated Rating$2.22$4.00Neutral$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper SandlerBMO Capital MarketsRaymond James FinancialMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.